Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
  • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/10—Cellular immunotherapy characterised by the cell type used
  • A61K40/19—Dendritic cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
  • A61K40/24—Antigen-presenting cells [APC]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/42—Cancer antigens
  • A61K40/4231—Cytokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/54—Interleukins [IL]
  • C07K14/5418—IL-7
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K16/244—Interleukins [IL]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

• the present invention relates generally to uses of mammalian cytokines. More specifically, the invention relates to identification of mammalian cytokine and inhibitors thereof that affect medical conditions such as allergy and inflammation.
• Cytokines mediate cellular activities in a number of ways. Cytokines support the proliferation, growth, and differentiation of pluripotential hematopoietic stem cells into vast numbers of progenitors comprising diverse cellular lineages making up a complex immune system. Proper and balanced interactions between the cellular components are necessary for a healthy immune response. The different cellular lineages often respond in a different manner when cytokines are administered in conjunction with other agents. Cytokines mediate communication between cells of the immune system, e.g., antigen presenting cells (APCs) and T lymphocytes. Dendritic cells (DCs) are the most potent of antigen presenting cells. See, e.g., Paul (ed.) (1993) Fundamental Immunology.
• APCs antigen presenting cells
• DCs Dendritic cells
• Antigen presentation refers to the cellular events in which a proteinaceous antigen is taken up, processed by antigen presenting cells (APC), and then recognized to initiate an immune response.
• the most active antigen presenting cells have been characterized as the macrophages (which are direct developmental products from monocytes), dendritic cells, and certain B cells.
• DCs are highly responsive to inflammatory stimuli such as bacterial lipopolysaccharides (LPS), and cytokines such as tumor necrosis factor alpha (TNF alpha). Cytokines or stimuli, such as LPS, can induce a series of phenotypic and functional changes in DC that are collectively referred to as maturation. See, e.g., Banchereau and Schmitt (eds.) (1995) Dendritic Cells in Fundamental and Clinical Immunology. Plenum Press, NY.
• Dendritic cells can be classified as, e.g., interstitial dendritic cells of the heart, kidney, gut, and lung; Langerhans cells in the skin and mucous membranes; interdigitating dendritic cells in the thymic medulla and secondary lymphoid tissue; and blood and lymph dendritic cells. Although dendritic cells in each of these compartments are CD45 + leukocytes that apparently arise from bone marrow, they can exhibit differences that relate to maturation state and microenvironment.
• Maturational changes in DCs include, e.g., silencing of antigen uptake by endocytosis, upregulation of surface molecules related to T cell activation, and active production of a number of cytokines including TNFalpha and IL- 12.
• cytokines including TNFalpha and IL- 12.
• DCs migrate to the T cell areas of secondary lymphoid organs to activate antigen specific T cells.
• Cytokines and immune cells mediate specific physiological mechanisms or pathways, e.g., pathways leading to the various inflammatory disorders.
• inflammatory disorders e.g., the allergic diseases, which include asthma, rhinitis, atopic dermatitis, and food allergy (see, e.g., A. B. Kay (2001) N. Engl. J. Med. 344:30-37).
• Allergic inflammation is the result of a complex immunological cascade leading to T cells to produce dysregulated TH2-derived cytokines such as IL-4, IL-5 and IL-13, where these cytokines trigger bronchial hyperreactvity, IgE production, eosinophilia, and mucus production (see, e.g., Busse and Lemanske, Jr. (2001) N. End. J. Med. 344:350-62; Holgate (2000) Br. Med. J. 320:231-234); and Renauld (2001) J. Clin. Pathol. 54:577-589).
• Inflammation and immune reconstitution are two situations where it is desirable to use pharmaceutical or therapeutic intervention to modulate lymphocyte activity or proliferation, e.g., by modulating interactions between APCs and T cells.
• Inflammatory conditions dependent on APC-T cell interactions include, e.g., psoriasis, the allergies, and bronchial hypersensitivity.
• Immune reconstitution the replenishment of the immune system, is useful in treating viral infections, e.g., HIV/ AIDS, and in treating patients undergoing cytoablation, where cytoablation is effected, e.g., with radiation therapy or chemotherapy.
• Psoriasis an inflammatory disease of the skin, has a prevalence in Western countries of over 4% (Granstein (1996) J. Clin. Inv. 98:1695-1696; Christophers (2001) Clin. Exp. Dermatol. 26:314-320).
• the disease is subject to frequent relapses, is occasionally life- threatening, and is frequently associated with arthritis, i.e., psoriatic arthritis.
• T cells and keratinocytes are necessary for the development and persistence of psoriasis (Greaves and
• Dendritic cells and mast cells for example, also contribute to psoriatic inflammation (Mrowietz, et al. (2001) Exp. Dermatol. 10:238-245; Ackermarm, et al (1999) Br. J. Dermatol. 140:624- 633).
• Bronchial hyperreactivity is the manifestation of pulmonary inflammatory diseases, including asthma, chronic obstructive pulmonary disease (COPD; chronic obstructive pulmonary disorder), chronic bronchitis, eosinophilic bronchitis, bronchiolitis, and viral bronchiolitis (Riffo-Vasquez and Spina (2002) Pharmacol. Therapeutics 94:185-211).
• COPD chronic obstructive pulmonary disease
• Asthma is a chronic disease characterized by increased bronchial responsiveness and by airway obstruction and inflammation. The disease accounts, e.g., for over 15% of pediatric emergencies (Crain, et al. (1995) Arch. Pediatr. Adolesc. Med. 149:893-901).
• APCs T cells, B cells, eosinophils, mast cells, and basophils, contribute to the mechanism of asthma.
• APCs present antigen to T cells which, in turn, provoke B cells to produce IgE.
• Eosinophils, basophils, and mast cells release IL-4 which, in turn, promotes the differentiation of T cells into TH2 cells that secrete IL-4, IL-5, IL-10, and IL-13 after antigen stimulation.
• the IL-4 and IL-13 secreted by the TH2 cells and other cells, promotes activation of B cells (Marone (1998) Immunol. Today 19:5-9).
• B cells are stimulated to produce IgE by two types of signals, IL-4 or IL-13, and direct contact from T cells (Barnes and Lemanske (2001) New Engl. J. Med. 344:350-362).
• the released IgE activates mast cells which, in turn, cause constriction of the airways.
• Eosinophils produce major basic protein which directly damages the airways.
• IL-5 plays a central role in the development, survival, and recruitment of eosinophils (Barnes and Lemanske, supra).
• COPD which involves infiltration of bronchioles with lymphocytes
• the disease is characterized by thickening of airway smooth muscle and inflammation of the airways, i.e., involving infiltration by monocytes, macrophages, CD4 + T cells, CD8 + T cells, and neutrophils in the lungs (Barnes (2000) Chest 1 17T0S-14S; Jeffery (1998) Thorax 53:129-136).
• Immune reconstitution is a condition where modulation of lymphocyte proliferation is desirable. Immune reconstitution is accomplished, e.g.. by bone marrow transplantation. Enhancing or stimulating T cell proliferation is desired in bone marrow transplantation following chemotherapy and in immune deficiency diseases, e.g., AIDS (Panteleo, et al. (1993) New Engl. J. Med. 328:327-335; Kovacs, et_al. (1995) New Engl. J. Med. 332:567- 575), as well as with use of therapeutic T cells, including genetically altered T cells (Terando and Chang (2002) Surg. Oncol. Clin. N. Am. 11 :621-643; Gottschalk, et al.
• Recipients of stem cell transplants experience delays in acquisition of fully functional lymphocytes, where these delays can extend beyond one year from the transplant.
• CD4 + T cell counts may be subnormal with bone marrow transplants, i.e., where the thymus has been damaged by radiotherapy (Novitzky and Davison (2001) Cytotherapy 3:211-220).
• stimulation of lymphocyte proliferation is a desirable goal because of the delays in T cell proliferation following bone marrow transplant, as well as in transplants where there the thymus is damaged.
• Cytoablation followed by bone marrow transplant or stem cell therapy is used in the treatment of a number of autoimmune diseases, e.g., rheumatoid arthritis, systemic lupus erythematosus, Crohn's diseaes, and multiple sclerosis (Breedveld (2000) Arthritis Res. 2:268-269; McColl et al. ( 1999) Ann. Intern. Med. 131 :507-509: Laar (2000) Arthritis Res. 2:270-275), as well as in treatment of cancers such as non-Hodgkin's lymphoma and leukemia (Kay, et al. (2002) Hematology fAm. Soc. Hematol. Educ. Program) 193-213; Hagemeister (2002) Cancer Chemother. Pharmocol. 49 Suppl. LS13-20).
• autoimmune diseases e.g., rheumatoid arthritis, systemic lupus ery
• GVHD graft-versus-host disease
• Ex vivo treatment of lymphocytes e.g., by treatment with cytokines or nucleic acids, followed by introduction into a subject is described. See, e.g., Ernerudh, et al. (2002) Curr. Med. Chem. 9:1497- 1505; Cavazzana-Calvo, et al. (2002) Semin. Hematol. 39:32-40; Gunzer and Grabbe (2001)
• the invention provides methods for modulating dendritic cells (DCs) for the treatment of inflammatory conditions dependent on APC/T cell interactions, and for effecting immune reconstitution.
• DCs dendritic cells
• Dendritic cells the professional antigen presenting cells
• T cell activation and prolilferation the professional antigen presenting cells
• DCs the professional antigen presenting cells
• Thymic stromal lymphopoietin (SEQ ID NO: 1) is a novel IL-7-like cytokine, cloned from a murine thymic stromal cell line (see, e.g., J. E. Sims et al.. (2000) J. Exp. Med. 192:671-680; and USSN 09/963,347, filed September 24, 2001).
• the mature coding region of human TSLP is amino acids 29-159 (Reche, et al. (2001) J Immunol. 167:336-343).
• the TLSP/IL-50-receptor is a heterodimer, consisting of the IL-7R-alpha chain (SEQ ID NO:2) and a common gamma-like receptor chain (TSLP receptor; TSLPR)
• mice TSLP/IL-50 supports murine early B and T cell developments (see, e.g. Levin et al. (1999) J. Immunol. 162:677-683; Ray, et al. (1996) Eur. J. Immunol. 26: 10-16).
• hTSLP/IL-50 activates CDl lc + DCs, but do not have any direct biological effects on B cells, T cells, NK cells, neutrophils, nor mast cells (see, e.g., Reche, et al., supra). This is in accordance with the co-expression of mRNA for hTSLP/IL-50 receptor delta2 subunit and the IL-7R-alpha chain in CDl lc + DCs, but not in other cell types. The mechanisms and pathogenesis of inflammation, in particular, allergic inflammation, are not fully understood, and as such several therapies are as yet unknown. The present invention provides evidence that hTSLP/IL-50 (SEQ ID NOT) can mediate various inflammatory disorders by its action on certain subsets of immune cells, in particular, dendritic cells.
• the present invention is based, in part, upon the discovery of the effect of hTSLP/IL-50 (SEQ ID NOT) on antigen presenting cell, e.g., dendritic cells (DC), activity, in particular, DC priming of T cells resulting in inflammation, e.g., psoriasis or allergic inflammation.
• antigen presenting cell e.g., dendritic cells (DC)
• DC dendritic cells
• the invention provides a method of modulating antigen presenting cell (APC) priming of a T cell comprising contacting the APC with an agonist of TSLP/IL-50 (SEQ ID NOT) or TSLP/IL-50 receptor (TSLP/IL-50R) (SEQ ID NOs:2, 3); or an antagonist of TSLP/IL-50 (SEQ ID NOT) or TSLP/IL-50R (SEQ ID NOs:2, 3).
• APC antigen presenting cell
• the T cell is a na ⁇ ve CD4 + T cell, a central memory T cell, or an effector memory T cell
• the APC is a CDl lc + dendritic cell (DC); wherein the priming stimulates the proliferation of the T cell; wherein the proliferation is polyclonal; or wherein the interaction between the APC and the T cell is autologous or allogeneic, or wherein the interaction is autologous and yields a central memory T cell phenotype.
• the agonist or antagonist comprises a humanized antibody; a monoclonal antibody; a polyclonal antibody; an Fab fragment; an F(ab') 2 fragment; or a peptide mimetic of an antibody; or wherein the agonist is TSLP/IL-50 (SEQ ID NOT), or an antigenic fragment thereof.
• the invention encompasses a method of treating a subject suffering from an immune disorder comprising treating with or administering an effective amount of an agonist of TSLP/IL-50 (SEQ ID NOT) or TSLP/IL-50 R (SEQ ID NOs:2,3); or an antagonist of TSLP/IL-50 (SEQ ID NOT) or TSLP/IL-50R (SEQ ID NOs:2, 3).
• the immune disorder is an inflammatory condition and the administration comprises an effective amount of an antagonist of
• TSLP/IL-50 (SEQ ID NO: 1) or TSLP/IL-50R (SEQ ID NOs:2, 3); wherein the immune disorder is psoriasis, psoriatic arthritis, or pulmonary inflammatory response; or wherein the pulmonary inflammatory disease is asthma or chronic obstructive pulmonary disorder (COPD).
• the immune disorder is immunodeficiency and the administration comprises an effective amount of an agonist of
• TSLP/IL50 (SEQ ID NOT); wherein the immunodeficiency is a result of cytoablation or viral infection causing immunosuppression; wherein the administration comprises ex vivo treatment of autologous or allogeneic antigen presenting cells (APCs); or wherein the administration comprises ex vivo treatment of APCs with an effective amount of an agonist of TSLP/IL50 (SEQ ID NOT).
• APCs autologous or allogeneic antigen presenting cells
• the invention also contemplates the above method, wherein the agonist or antagonist comprises a humanized antibody; a monoclonal antibody; a polyclonal antibody; an Fab fragment; an F(ab') 2 fragment; or a peptide mimetic of an antibody; or wherein the agonist is TSLP/IL-50 (SEQ ED NOT), or an antigenic fragment thereof.
• a method of inducing production of IL-4, IL-5, and IL-13 by a T cell comprising contacting an APC with an agonist of TSLP/IL-50 or TSLP/IL-50 receptor, and priming the T cell with the APC.
• the invention also encompasses a method of modulating TH2 response in a subject comprising administration of an agonist of TSLP/IL-50 (SEQ ID NOT) or TSLP/IL-50 receptor (TSLP/IL-50R) (SEQ ID NOs:2, 3); or an antagonist of TSLP/IL-50 (SEQ ID NOT) or TSLP/IL-50R (SEQ ID NOs:2, 3).
• Activation As it applies to cells or to receptors, may have the same meaning, e.g., activation, stimulation, or treatment of dendritic cells (DC) with a ligand, unless indicated otherwise by the context or explicitly.
• administering and “treatment,” as it applies to treatment of a human subject or animal, refers to contact of a pharmaceutical, therapeutic, or diagnostic agent or composition to the subject or animal.
• administering and “treatmenf'also means ex vivo treatment to, e.g., a cell, tissue, or organ, followed by contact of the cell, tissue, or organ, to the subject or animal, even where the agent or composition has been metabolized, altered, or degraded, during the ex vivo treatment.
• Allogeneic refers, e.g., to an interaction where the major histocompatibility complex (MHC) of a first cell is recognized as foreign by a second cell.
• Autologous refers, e.g., to an interaction where the MHC of a first cell is recognized as self by a second cell (Abbas, et al. (2000) Cellular and Molecular Immunology. 4 h ed., W.B. Saunders Co., Philadelphia).
• Effective amount means an amount sufficient to ameliorate a symptom or sign of the medical condition.
• “Polyclonal” expansion or proliferation means that proliferation of a cell involves maintenance of the phenotype, while “oligoclonal” expansion or proliferation means that the phenotype is altered (Duarte, et al. (2002) Gene Therapy 9: 1359-1368).
• "Sensitivity,” e.g., sensitivity of T cell receptor (TCR), means that binding of a ligand to TCR results in a detectable change in the TCR, or in events or molecules specifically associated with the TCR, e.g., TCR conformational change or phosphorylation, change in proteins associated with the TCR, or change in TCR-associated genetic expression.
• hTSLP/IL-50 (SEQ ID NOT) (a.k.a. Thymic Stromal Lymphopoietin; TSLP) was originally discovered in the mouse and found to play a similar role as its homologue IL-7 in supporting early B and T cell development (see, e.g., Sims, supra; Levin et al.. supra; and Ray, eLal., supra).
• Mouse TSLP/IL-50 did not activate mouse DCs isolated from spleen, or generated from monocytes or bone marrow.
• the present invention demonstrates that human TSLPTL-50 (SEQ ID NOT) is a novel DC activator.
• hTSLP/IL- 50 displays several unique features, when compared with other DC activation factors, e.g., CD40-ligand, LPS, or IL-7. For example, it induces the highest levels of CD40 and CD80 on DCs; it activates DCs to induce the most potent na ⁇ ve CD4 T cell proliferation and expansion; it does not appear to induce DCs to produce several of the known proinflammatory cytokines, but rather it induces the production of TH2 attracting chemokines TARC and MDC; and it causes DCs to prime na ⁇ ve CD4 + T cells to produce high levels of the TH2 cytokines IL-4, IL-5, IL-13, and TNFalpha.
• DC activation factors e.g., CD40-ligand, LPS, or IL-7.
• hTSLP/IL-50 SEQ ID NOT represent a critical mediator in uncontrolled inflammation, in particular, allergic inflammation.
• Activation of DCs appears to be a critical step in the pathogenesis of TH2-mediated allergic inflammations, e.g., asthma.
• Dendritic cells presenting allergen to Th2 cells activate the Th2 cells to release cytokines, e.g., IL-4, IL-5, and IL-13, where these cytokines contribute in differing ways to the pathology of asthma.
• cytokines e.g., IL-4, IL-5, and IL-13, where these cytokines contribute in differing ways to the pathology of asthma.
• IL-4 stimulates increases in airway endothelial cell adhesion molecules and chemokine production
• IL-5 provokes eosinophil production
• IL-13 promote smooth muscle hyperreactivity (Lewis (2002) Curr. Opinion Immunol. 14:644-651).
• IL-4 stimulated cell adhesion molecules serve as receptors for inflammatory cells (Striz, etal (1999) Am J. Phvsiol. 277:L58-L64).
• IL-4 and IL-13 activate B cells, resulting in B cell proliferation and synthesis of IgE (Busse and Lemanske (2001 New Engl. J. Med. 344:350-362).
• IL-4 is overexpressed in airways of allergic asthmatics, while IL-13 is overexpressed in airways in both allergic and non-allergic asthma (Wills-Karp, e al (1998) Science 282:2258-2260).
• IL-4 seems more important in primary allergen sensitization, while IL-13 appears more important during secondary exposure to allergen (Kips (2001) Eur. Resp. J. Suppl. 34:24s-33s).
• DCs from allergic individuals preferentially induce a TH2-type response with (see, e.g.,Hammad et_aT, (2001) Blood 98, 1135-41) or without (see, e.g., P. A. Stumbles, supra: McWilliam etal. (1996) J. Exp. Med. 184:2429-32; N. Novak etal- (1999) Allergy 54:792-803; Tunon-De-Lara etal- (1996) Clin. EXP.
• hTSLP/IL-50 (SEQ ID NOT) is highly expressed by keratinocytes of atopic dermatitis and hTSLP/IL-50 (SEQ ID NO:l)-activated DCs strongly prime na ⁇ ve CD4 + T cells to produce IL-4, IL-5, IL-13 and TNFalpha, suggest that hTSLP/IL-50 (SEQ ID NOT) represents the missing critical factor in understanding the pathogenesis of allergic diseases.
• hTSLP/IL-50 (SEQ ID NOT) produced by epithelial cells, or other stromal cells at the site of antigen entry, will activate DCs and stimulate DCs to produce TH2-attracting chemokines such as TARC and MDC.
• hTSLP/IL-50 (SEQ ID NO: l)-activated DCs migrate into the draining lymph nodes to induce allergen-specific T cell proliferation and differentiation into TH2 cells. These allergen-specific TH2 T cells may migrate back towards TARC and MDC within the original site of inflammation, to trigger allergic inflammation, thus establishing a direct functional link between epithelial cells, DCs and T cell-mediated immune responses.
• IL-10 has been historically included as a TH2 cytokine(see, e.g., Abbas, et al. (1996) Nature 383:787-793), its contribution to the TH2-mediated allergic inflammation has been controversial. Whereas some studies showed that IL- 10 mRNA levels in lung, gut and skin were increased in patients with allergic asthma or atopic dermatitis (see, e.g., Robinson et al. (1996) Am. J. Respir. Cell Mol. Biol.
• IL-4, IL-5, IL-13 and TNFalpha, and decreased levels of IL-10 and IFN-gamma produced by hTSLP/IL-50 stimulated-DC activated T cells may represent the real allergic inflammatory cytokines underlying the pathophysiology of atopic dermatitis or asthma.
• IL-10 is an anti-inflammatory cytokine, but not a pro-allergic TH2 cytokine. Further described is the first evidence that epithelial cells of skin and mucosa directly interact with DCs during allergic inflammation by producing TSLP/IL-50 (SEQ ID NOT).
• hTSLP/IL-50 (SEQ ID NOT) not only potently activates DCs, but also endorse DCs with the ability to polarize na ⁇ ve T cells to produce pro-allergic TH2 cytokines.
• hTSLP/IL-50 (SEQ ID NO: 1) represents a novel target to block inflammatory and allergic diseases.
• the present invention provides methods and reagents to enhance the TH2-mediated response by agonizing the activities of TSLP/IL-50 (SEQ ID NOT). Enhance of this response is useful in the treatment of disorders due to suppression of the immune system, e.g., HIV. Augmentation of dendritic cell activity will be useful in the treatment of viral, bacterial, or fungal infections. TSLP/IL-50 (SEQ ID NOT) and/or agonists thereof will also be useful as vaccine adjuvants.
• Suppression of DC response is useful for the treatment of several immune disorders and condition, e.g., allergic inflammation, bronchial hyperreactivity, asthma, rhinitis, food allergy, transplant rejection, graft-vs-host disease, autoimmune diseases, viral infections that cause immunosuppression, psoriasis, and atopic dermatitis.
• immune disorders and condition e.g., allergic inflammation, bronchial hyperreactivity, asthma, rhinitis, food allergy, transplant rejection, graft-vs-host disease, autoimmune diseases, viral infections that cause immunosuppression, psoriasis, and atopic dermatitis.
• Blockage of the activities of hTSLP/IL-50 can be achieved by antagonists of the cytokine, e.g., antibodies to the ligand, antibodies to the receptor, etc. Interference with the ligand-receptor interaction has proven to be an effective strategy for the development of antagonists.
• Another means is to use a ligand mutein which retains receptor binding activity, but fails to induce receptor signaling.
• the mutein may be a competitive inhibitor of signaling ligand.
• small molecule libraries may be screened for compounds which may block the interaction or signaling mediated by an identified ligand-receptor pairing.
• the present invention provides for the use of an antibody or binding composition which specifically binds to a specified cytokine ligand, preferably mammalian, e.g., primate, human, cat, dog, rat, or mouse.
• cytokine ligand preferably mammalian, e.g., primate, human, cat, dog, rat, or mouse.
• Antibodies can be raised to various cytokine proteins, including individual, polymorphic, allelic, strain, or species variants, and fragments thereof, both in their naturally occurring (full-length) forms or in their recombinant forms. Additionally, antibodies can be raised to receptor proteins in both their native (or active) forms or in their inactive, e.g., denatured, forms.
• Anti-idiotypic antibodies may also be used.
• a number of immunogens may be selected to produce antibodies specifically reactive with ligand or receptor proteins.
• Recombinant protein is a preferred immunogen for the production of monoclonal or polyclonal antibodies.
• Naturally occurring protein from appropriate sources, e.g., primate, rodent, etc., may also be used either in pure or impure form.
• Synthetic peptides made using the appropriate protein sequences, may also be used as an immunogen for the production of antibodies.
• Recombinant protein can be expressed and purified in eukaryotic or prokaryotic cells as described, e.g., in Coligan, et al. (eds. 1995 and periodic supplements) Current Protocols in Protein Science.
• an immunogen preferably a purified protein
• animals are immunized with the mixture.
• the animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the protein of interest.
• blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be performed if desired. See, e.g., Harlow and Lane; or Coligan. Immunization can also be performed through other methods, e.g., DNA vector immunization. See, e.g., Wang, etal. (1997) Virology 228:278-284.
• Monoclonal antibodies may be obtained by various techniques familiar to researchers skilled in the art.
• spleen cells from an animal immunized with a desired antigen are immortalized, commonly by fusion with a myeloma cell.
• Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods known in the art. See, e.g., Doyle, et al. (eds. 1994 and periodic supplements) Cell and Tissue Culture: Laboratory Procedures. John Wiley and Sons, New York, NY.
• Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells may be enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate host.
• Antibodies or binding compositions including binding fragments, single chain antibodies, Fv, Fab, or F(ab') 2 fragments of antibodies, against predetermined fragments of ligand or receptor proteins can be raised by immunization of animals with conjugates of the fragments of the ligand or receptor proteins with carrier proteins.
• Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective protein. These monoclonal antibodies will usually bind with at least a K j of about 1 mM, more usually at least about 300 ⁇ M, typically at least about 10 ⁇ M, more typically at least about 30 ⁇ M, preferably at least about 10 ⁇ M, and more preferably at least about 3 ⁇ M or better.
• mAbs monoclonal antibodies
• mammalian hosts such as mice, rodents, primates, humans, etc.
• Description of techniques for preparing such monoclonal antibodies may be found in, e.g., Stites, et al. (eds.) Basic and Clinical Immunology, 4th ed., Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice. 2nd ed..
• this method involves injecting an animal with an immunogen. The animal is then sacrificed and cells taken from its spleen, which are then fused with myeloma cells. The result is a hybrid cell or "hybridoma" that is capable of reproducing in vitro. The population of hybridomas is then screened to isolate individual clones, each of which secrete a single antibody species to the immunogen. In this manner, the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.
• polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal.
• labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature.
• Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see, Cabilly, U.S. Pat. No. 4,816,567; and Queen, et al.
• Antibodies are merely one form of specific binding compositions.
• Other binding compositions which will often have similar uses, include molecules that bind with specificity to ligand or receptor, e.g., in a binding partner-binding partner fashion, an antibody-antigen interaction, or in a natural physiologically relevant protein-protein interaction, either covalent or non-covalent, e.g., proteins which specifically associate with desired protein.
• the molecule may be a polymer, or chemical reagent.
• a functional analog may be a protein with structural modifications, or may be a structurally unrelated molecule, e.g., which has a molecular shape which interacts with the appropriate binding determinants.
• Antibody binding compounds, including binding fragments, of this invention can have significant diagnostic or therapeutic value.
• binding compounds can be useful as non-neutralizing binding compounds and can be coupled to toxins or radionuclides so that when the binding compound binds to the antigen, a cell expressing it, e.g., on its surface, is killed. Further, these binding compounds can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.
• TSLP/IL-50 SEQ ID NOT
• Regions of increased antigenicity in human TSLP/IL-B50 include KAAYL (amino acids 40-44); KD (49-50); KS (59-60); PHC (73-75); ASLAK (91-95); TKAAL
• Antibodies against IL- 7Ralpha are available (Pandey, etal-, supra).
• Anti-TSLPR antibodies are available (R & D Systems, Minneapolis, MN, cat. no. MAB981; DNAX Research, Inc., Palo Alto, CA).
• Antibodies are also prepared against TSLPR (SEQ ID NO:3) by immunization with, e.g., regions of increased antigenicity determined by the Welling plot of Vector NTI® Suite (Informax, Inc, Bethesda, MD). Regions of increased antigenicity in human TSLPR include HYR (amino acid residues 59-61); YYLKP (115-119); KHV (123-
• Agonists include the TSLP/IL-50 (SEQ ID NOT) cytokine protein itself, which can be used to induce receptor signaling.
• the invention provides means to address various inflammation related disorders, e.g., allergic inflammation.
• the etiology and pathogenesis are often not well understood, but they cause significant discomfort or morbidity in patients.
• administration of TSLP/IL-50 (SEQ ID NOT) to CDl lc " DCs results in the priming of na ' ⁇ ve CD4 + T cells to produce IL-4, IL-5, IL-13, and TNFalpha, and thus agonists or antagonists may offer a therapeutic modality to enhance or suppress the immune system.
• Diagnostic methods include such aspects as prediction of prognosis; definition of subsets of patients who will either respond or not respond to a particular therapeutic course; diagnosis of bone or immune related disorders or subtypes of these disorders; or assessing response to therapy.
• the invention contemplates an antibody, or binding fragment thereof, comprising a detectable label, e.g., a fluorescent, epitopic, enzymatically active, or radioactive label.
• Antagonists or agonists to TSLP/IL-50 (SEQ ID NOT) activity can be implicated in a manner suggesting significant therapeutic effects, e.g., to decrease or prevent occurrence of symptoms.
• the antagonists and/or agonists of the present invention can be administered alone or in combination with another inhibitor or agonist of the same or accompanying pathway; or other compounds used for the treatment of symptoms, e.g., antagonists, or steroids such as glucocorticoids. This may be effected by either direct administration of the agonist or antagonist, or perhaps using a gene therapy strategy.
• Antagonism may be effected, e.g., by antisense treatment, antibodies, or other suppression of TSLP/IL-50 (SEQ ID NOT) effects.
• compositions including the antibody, binding composition thereof, cytokine agonist, or small molecule antagonist
• the entity is admixed with a pharmaceutically acceptable carrier or excipient which is preferably inert.
• a pharmaceutically acceptable carrier or excipient which is preferably inert.
• Antibodies, binding compositions, or cytokines are normally administered parentally, preferably intravenously. Since such proteins or peptides may be immunogenic they are preferably administered slowly, either by a conventional i.v. administration set or from a subcutaneous depot, e.g. as taught by Tomasi, et al, U.S. Pat. No. 4,732,863. Means to minimize immunological reactions may be applied.
• Small molecule entities may be orally active.
• the biologies When administered parenterally the biologies will be formulated in a unit dosage injectable form (solution, suspension, emulsion) in association with a pharmaceutically acceptable parenteral vehicle.
• a pharmaceutically acceptable parenteral vehicle Such vehicles are typically inherently nontoxic and nontherapeutic.
• the therapeutic may be administered in aqueous vehicles such as water, saline, or buffered vehicles with or without various additives and/or diluting agents.
• a suspension such as a zinc suspension
• a suspension can be prepared to include the peptide.
• Such a suspension can be useful for subcutaneous (SQ) or intramuscular (IM) injection.
• the proportion of biologic and additive can be varied over a broad range so long as both are present in effective amounts.
• the antibody is preferably formulated in purified form substantially free of aggregates, other proteins, endotoxins, and the like, at concentrations of about 5 to 30 mg/ml, preferably 10 to 20 mg/ml.
• the endotoxin levels are less than 2.5 EU/ml. See, e.g., Avis, et al. (eds.)(1993) Pharmaceutical Dosage Forms: Parenteral Medications.
• an administration regimen for a therapeutic depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of the target cells, timing of administration, etc.
• an administration regimen maximizes the amount of therapeutic delivered to the patient consistent with an acceptable level of side effects.
• the amount of biologic delivered depends in part on the particular entity and the severity of the condition being treated. Guidance in selecting appropriate antibody doses is found in, e.g. Bach et al.. chapter 22, in Ferrone, et al. (eds.) (1985) Handbook of Monoclonal Antibodies. Noges Publications, Park Ridge, NJ; and Haber, et al.
• cytokine or small molecules are determined using standard methodologies.
• Determination of the appropriate dose is made by the clinician, e.g., using parameters or factors known or suspected in the art to affect treatment or predicted to affect treatment. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved relative to any negative side effects.
• Important diagnostic measures include those of symptoms of, e.g., the inflammation or level of inflammatory cytokines produced.
• a biologic that will be used is derived from the same species as the animal targeted for treatment, thereby minimizing a humoral response to the reagent.
• the total weekly dose ranges for antibodies or fragments thereof, which specifically bind to ligand or receptor range generally from about 10 ⁇ g, more generally from about 100 ⁇ g, typically from about 500 ⁇ g, more typically from about 1000 ⁇ g, preferably from about 5 mg, and more preferably from about 10 mg per kilogram body weight. Generally the range will be less than 100 mg, preferably less than about 50 mg, and more preferably less than about 25 mg per kilogram body weight. Agonist or small molecule therapeutics may be used at similar molarities.
• the weekly dose ranges for antagonists of cytokine receptor mediated signaling range from about 1 ⁇ g, preferably at least about 5 ⁇ g, and more preferably at least about 10 ⁇ g per kilogram of body weight. Generally, the range will be less than about 1000 ⁇ g, preferably less than about 500 ⁇ g, and more preferably less than about 100 ⁇ g per kilogram of body weight. Dosages are on a schedule which effects the desired treatment and can be periodic over shorter or longer term. In general, ranges will be from at least about 10 ⁇ g to about 50 mg, preferably about 100 ⁇ g to about 10 mg per kilogram body weight. Cytokine agonists or small molecule therapeutics will typically be used at similar molar amounts, but because they likely have smaller molecular weights, will have lesser weight doses.
• the present invention also provides for administration of biologies in combination with known therapies, e.g., steroids, particularly glucocorticoids, which alleviate the symptoms, e.g., associated with inflammation, or antibiotics or anti-infectives.
• Daily dosages for glucocorticoids will range from at least about 1 mg, generally at least about 2 mg, and preferably at least about 5 mg per day. Generally, the dosage will be less than about 100 mg, typically less than about 50 mg, preferably less than about 20 mg, and more preferably at least about 10 mg per day. In general, the ranges will be from at least about 1 mg to about 100 mg, preferably from about 2 mg to 50 mg per day. Suitable dose combinations with antibiotics, anti-infectives, or anti-inflammatories are also known.
• Typical mammalian hosts will include mice, rats, cats, dogs, and primates, including humans.
• An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient, the method route and dose of administration and the severity of side affects.
• an effective amount is in ratio to a combination of components and the effect is not limited to individual components alone.
• An effective amount of therapeutic will decrease the symptoms typically by at least about 10%; usually by at least about 20%; preferably at least about 30%; or more preferably at least about 50%.
• the present invention provides reagents which will find use in therapeutic applications as described elsewhere herein, e.g., in the general description for treating disorders associated with the indications described above. Berkow (ed.) The Merck Manual of Diagnosis and Therapy. Merck & Co., Rahway, N.J.; Braunwald, et al. (eds.) (2001) Harrison's Principles of Internal Medicine, McGraw-Hill, NY; Gilman, et al. (eds.)
• CDl lc + DC were purified from adult blood buffy coats of healthy volunteer blood donors (Stanford Medical School Blood Center, Stanford, CA) after separation of PBMC by
• CDl lc + CD4 + T cells were isolated using a Vantage FACsorter® (Becton Dickinson, Franklin Lakes, NJ) to reach >99% purity.
• CDl lc + DC were cultured immediately after sorting in RPMI containing 10% FCS,
• TSLP/IL-50 SEQ ID NOT
• IL-7 50 ng/ml
• LPS LPS
• CD40-ligand-transfected L-fibroblasts 2.5 x 104/well
• Viable DC were first counted using trypan blue exclusion of dead cells.
• Remaining cells were stained with a variety of mouse anti -human FITC-conjugated monoclonal antibodies (mAb) including anti-HLA-DR (Becton Dickinson, Franklin Lakes, NJ), anti-CD40, CD80 and CD86 (all from Pharmingen, San Diego, CA) or an IgGl isotype control (Becton Dickinson, Franklin Lakes, NJ), and were analyzed with a FACScan® flow cytometer (Becton Dickinson, Franklin Lakes, NJ). Dead cells were excluded based on side and forward scatter characteristics.
• mAb mouse anti -human FITC-conjugated monoclonal antibodies
• TSLP/IL-50 SEQ ID NOT
• IL-7 CD40-ligand
• LPS all upregulated surface HLA-DR
• TSLP/IL-50 SEQ ID NOT
• TSLP/IL-50 SEQ ID NOT
• TSLP/IL-50 SEQ ID NO: 1
• SEQ LD NOT neutralizing monoclonal antibodies specific for human TSLP/IL-50
• both TSLP/IL-50 sti ulated-DCs and CD40L-DCs display long dendrites, and express HLA-DR and dendritic cell-lysosome-associated membrane glycoprotein (DC-LAMP), when compared with medium-DCs or IL-7-DCs.
• DC-LAMP is a DC activation marker.
• DC-LAMP is rapidly induced by TNFalpha, LPS, or CD40L, and may be used for antigen presentation ( Saint- Vis, et al. (1998) Immunity 9:325-336).
• CDl lc + DC were harvested after 24h of culture in different conditions, washed twice to remove any cytokine and co-cultured with 5xl0 4 freshly purified allogeneic na ⁇ ve CD4 + T cells in round-bottom 96-well culture plates. Co-cultures were carried out in triplicate at increasing DC/T cell ratios. DC and T cells alone were used as controls. After 5 days, cells were pulsed with 1 mCi 3 H-thymidine (Amersham Biosciences Corp., Piscataway, NJ) for
• TSLP/IL-50 stimulated-DCs induced the strongest na ⁇ ve CD4 T cell proliferation in allogeneic mixed lymphocyte reaction, when compared to CD40L-DCs, LPS-DCs or IL-7-DCs.
• TSLP/IL-50 (SEQ ID NO:l)- activated DCs still induced a very strong allogeneic na ' ⁇ ve CD4 T cell proliferation, which was about 10 times stronger than that induced by CD40L-DCs.
• TSLP/IL-50 stimulated-DCs induced a 2.5 to 10-fold increase in total T cell numbers, more than that induced by CD40L-DCs, LPS-DC or IL-7-DC. Therefore, human TSLP/IL-50 (SEQ ID NOT) represents one of the most potent DC activation factors and TSLP/IL-50 stimulated-DC induce the most impressive allogeneic na ⁇ ve CD4 T cell proliferation and expansion.
• T cells were harvested at day 6 of the co-culture, washed twice and re-stimulated with PMA and ionomycine in flat bottom 96- or 48-well plates at a concentration of lxl0 ⁇ /ml. After 2.5h, Brefeldin A was added at lOmg/ml. After 5h, cells were harvested, fixed with 2% formaldehyde, permeabilized with 10% saponin and stained with PE- conjugated mAbs to IL-4, IL-5, IL-10, IL-13 and TNFalpha and FITC-conjugated mAb to IFN-gamma (all from Pharmingen, San Diego, CA). Stained cells were analyzed on a FACScan ® flow cytometer (Becton Dickinson, Franklin Lakes, NJ).
• TNFalpha TNFalpha
• 12 different chemokines TARC, DCCK1, MDC, MCP1, MCP2, MCP3alpha, MCP4, eotaxin, MIP3, MIG, Rantes and IL-8.
• TSLP/IL-50-treated DCs did not produce mRNA for all the pro-inflammatory cytokines tested, but produced high levels of mRNA for the chemokines TARC and MDC.
• TLSP-activated DCs did not produce detectable amounts of pro-inflammatory cytokines IL-lbeta, IL-6, IL-12p70 and TNFalpha, but high levels of the chemokines TARC and MDC (Reche, et al. (2001) J. Immunol. 167:336-343).
• TARC and MDC preferentially attract CCR4-expressing TH2 cells.
• CD4 + CD45RA + na ⁇ ve T cells purified from adult peripheral blood were co-cultured with DCs at a 1/5 ratio for 6 days, washed to remove all cytokines, re-stimulated 24 hours with anti-CD3 and anti-CD28, and cytokine production was measured in the culture supernatant by ELISA. Strikingly, TSLP/IL-50 stimulated-DCs induce na ⁇ ve CD4 T cells to produce the highest levels of TH2 cytokines IL-4, IL-5 and IL-13, together with the pro- inflammatory cytokine TNFalpha.
• TSLP/IL-50 stimulated-DCs induce na ⁇ ve CD4+ T cells to produce the lowest levels of anti-inflammatory cytokine IL-10 and THl cytokine IFN- gamma, when compared with DCs cultured with medium alone, or other activators.
• the ability of TSLP/IL-50 stimulated-DCs to induce na ⁇ ve CD4 T cells to produce high IL-4, IL-13 and TNFalpha and low IFN-gamma and IL-10 was confirmed by intracellular cytokine staining.
• TSLP/IL-50 (SEQ ID NOT)-DCs induced na ⁇ ve CD4 T cells to produce a very unique set of cytokines, which is distinct from a THl profile (IFN- gamma) or a classical TH2 profile (IL-4, IL-5 and IL-10).
• TSLP/IL-50 stimulated-DC- activated CD4 T cells produced the highest levels of TNFalpha, one of the most potent pro- inflammatory cytokines, when compared with CD4 T cells activated respectively by medium-DC, IL-7-DC, CD40L-DC or LPS-DC.
• TSLP/IL-50 stimulated- DC appeared to inhibit CD4+ T cells to produce IL-10, a potent anti-inflammatory cytokine (see, e.g., Moore, et al. (2001) Annu Rev Immunol 19:683-765) as well as IFN-gamma, a THl cytokine which can cross inhibit TH2 response (Abbas, et al. (1996) Nature 383:787- 793).
• TSLP/IL-50 stimulated-DCs induce robust TH2 allergic inflammation by promoting na ⁇ ve CD4 + T cells to produce IL-4, IL-5 and IL-13, in the presence of a strong pro-inflammatory cytokine TNFalpha, and in the absence of two physiologic inhibitors of
• Th2 inflammation IL-10 and IFN-gamma.
• TSLP/IL-50 stimulated-DCs further enhance TH2 -mediated inflammation by producing chemokines such as TARC and MDC, which preferentially recruit TH2 cells into the original inflamed tissues (see, e.g., Imai et al. (1999) Int. Immunol. 11:81-88: Andrew etal. (1998) J. Immunol. 161 :5027-5038; Andrew et al. (2001) J. Immunol. 166:103-111: Vestergaard et al. (2000) J. Invest. Dermatol.
• TSLP/IL-50 (SEQ ID NOT) mRNA was analyzed by real time quantitative PCR (Taqman®) in a panel of cDNA libraries from different primary cells or cell lines, and a panels of FACS-sorted primary cells (cell purity over 99%).
• TSLP/IL-50 (SEQ ID NOT) expression was not found in most hematopoietic cell types, including B cells, T cells, NK cells, granulocytes, macrophages, monocyte subsets, and DC subsets.
• hTSLP/IL-50 (SEQ ID NOT) was found to be highly expressed by cultured human primary stromal cells such as skin keratinocytes, epithelial cells, smooth muscle cells, and lung fibroblasts. Bronchial smooth muscle cells and skin keratinocytes activated respectively by IL-4, IL-13 and TNFalpha, or TNFalpha and IL-lbeta appear to express higher hTSLP/IL-50 (SEQ ID NOT), when compared with medium only controls. TSLP/IL-50 (SEQ ID NOT) expression was not found in endothelial cells. Therefore, hTSLP/IL-50 (SEQ ID NOT) mRNA is mainly expressed by most stromal cell types and mast cells, but not by most hematopoietic cell types and endothelial cells.
• BSMC bronchial smooth muscle cells
• NHLF normal human lung fibroblasts
• NHEK normal human epidermal keratinocytes
• MRC5 lung fibroblast cell line
• TSLP/IL-50 mRNA by human bronchial smooth muscle cells (BSMC) exposed to various cytokines was assessed by Taqman® and ELIS A following treatment of cells with various cytokines, as described in Soumelis, et al. (2002) Nature Immunol. 3:673-680; Reche, etal- (2001) J. Immunol. 167:336-343). Expression of mRNA levels was adjusted as units relative to expression of 18s RNA.
• IL-8 production from stromal cells was used as a control (Table IB).
• Table IB A comparison across the four cell lines tested revealed differences in trends in TSLP-IL-50 expression and
• hTSLP/IL-50 (SEQ ID NOT) protein, immunohistology was investigated. Samples were stained using mAb 6NE0112F3, which specifically recognizes hTSLP/IL-50. Human tonsils contain crypt epithelium, which lines the crypts and which frequently harbor viruses and bacteria and represents the sites of antigen-entry and constitutive inflammation, and squamous epithelium, which lines the tonsil surface. Among all five different tonsillar samples, hTSLP/IL-50 (SEQ ID NOT) was found to be constitutively expressed by crypt epithelial cells, which are in close contact with DC-LAMP positive lymphocytes and activated dendritic cells.
• hTSLP/IL-50 (SEQ ID NOT) contributes to the constitutive inflammation within the crypt epithelium and the sporadic inflammation within the squamous epithelium.
• hTSLP/IL-50 SEQ ID NOT expression was associated with Th2-type allergic inflammation in vivo
• hTSLP/IL-50 protein expression was analyzed in skin lesions, including atopic dermatitis (a TH2 mediated allergic disease), nickel- induced contact dermatitis (a IFN-gamma-producing CD8 + T cells mediated allergic disease) and disseminated lupus erythematosus (a THl -mediated disease). While hTSLP/IL-50 was not detectable in normal skin, and non-lesional skin of atopic dermatitis, high expression of hTSLP/IL-50 was found in keratinocytes of acute (4 patients) and chronic atopic dermatitis (6 patients).
• hTSLP/IL-50 The expression of hTSLP/IL-50 was found mainly in keratinocytes of the apical layers of the epidermis, ranging from small foci to the whole apical areas in both acute and chronic atopic dermatitis. hTSLP/IL-50 was not found in skin lesions from nickel-induced allergy contact dermatitis and disseminated lupus erythematosus. VI. Langerhans cell migration and activation.
• hTSLP/IL-50 SEQ ID NOT expression in atopic dermatitis associates with DC activation
• hTSLP/IL-50 was stained together with either langerin (a Langerhans cell marker), or DC-LAMP (a DC activation marker), by double irnmunohistology.
• langerin a Langerhans cell marker
• DC-LAMP a DC activation marker
• LAMP "1' DCs within the dermis. Many of the DC-LAMP + DCs within the dermis express langerin, showing that epidermal Langerhans cells are activated and migrate into the dermis. Thus, hTSLP/IL-50 expression by keratinocytes of atopic dermatitis contribute directly to the activation of Langerhans cells, which migrate into the draining lymph nodes and prime allergen-specific TH2 responses.
• TSLP/IL-50 expression of TSLP/IL-50 was determined by Taqman®, as described previously. The relative expression of TSLP/IL-50 in the indicated cells was: cultured lung fibroblasts (-H-++); cultured bronchial smooth muscle (++++); prostate stromal cells (++); mammary stromal cells (+); mammary epithelial cells (+); hepatofibroblasts (+); skin keratinocytes (+).
• TSLP/IL-50 was also determined by histological methods. Thymic epithelial cells were stained with tagged anti-TSLP/IL-50 antibody, as described in Soumelis, et al.. supra. TSLP/IL-50 was not detected in keratinocytes from normal skin and in non-lesional skin sections from atopic dermatitis, while high expression was found in keratinocytes of acute and chronic atopic dermatitis. In normal skin, expression was not found in sweat glands, eccrine glands, and hair follicles. TSLP/IL-50 expression was also expressed by thymic epithelial cells (Hassal corpuscules), as determined by histology. VIII. Allogeneic and autologous hTSLP/IL-50-treated DC both induce proliferation of na ⁇ ve CD4+ T cells.
• Na ⁇ ve CD4+ T cells were exposed to allogeneic dendritic cells prepared under one of five different test conditions, followed by assessment of proliferation of the T cells. The five conditions are described in Table 2. Proliferation was determined by 3H-thymidine incorporation assays. In allogeneic reactions, DC treated with TSLP/IL-50 (SEQ ID NOT) produced the greatest increased in T cell proliferation, while DC treated with other agents resulted in lesser or much lesser T cell proliferation.
• TSLP/IL-50 SEQ ID NOT-treated DC stimulates proliferation of na ⁇ ve CD4+ T cells.
• TSLP/IL-50-activated DC were mixed with autologous na ⁇ ve CD4 + T cells followed by an assessment of the profile of subspecies of T cell receptor in the pool of expanded, proliferating T cells.
• the subspecies of T cell receptor assayed for were TCRV ⁇ l, TCRV ⁇ 2, TCRV ⁇ 3, TCRV ⁇ 5, TCRV ⁇ 8, TCRV ⁇ l4, TCRV ⁇ l7, TCRV ⁇ 22, and TCRV ⁇ 23.
• T cells treated with Streptococcus endotoxin B-activated DC The untreated control population of T cells contained subspecies of T cell receptor as indicated: TCRV ⁇ l (about 3%), TCRV ⁇ 2 (about 8%), TCRV ⁇ 3 (about 6%), TCRV ⁇ 5 (about 2%), TCRV ⁇ (about 4%), TCRV ⁇ l4 (about 2.5%), TCRV ⁇ l 7 (about 7%), TCRV ⁇ 22 (about 2.5%), and TCRV ⁇ 23 (about 0.2%).
• Control incubation with IL-7 (no DC) also resulted in polyclonal expansion of T cells, while control incubation with endotoxin- treated DC resulted in the selected expansion of T cells bearing TCRV ⁇ 3 and TCRV ⁇ l7.
• CD4+ T cells exposed to IL-7-activated DC, to LPS-activated DC, to poly I:C-activated DC, to CD40L-activated DC, and to medium-treated DC. Essentially all control incubations resulted in little or no increase in T cell number, though a 3 -fold increase in T cell number was found at day 6 with LPS-activated DCs.
• na ⁇ ve CD4+ T cells before and after treatment with TSLP/IL-50 (SEQ ID NOT)-activated DC was determined. Phenotype was assessed by measuring the following markers on the T cells: CD45RA; CD45RO; CD25; CD62L; and CCR7. Na ⁇ ve T cells have the phenotype CD45RA + , CD45RO " , CD25-, CD62L + , and
• T cells expanded by autologous reaction rather than allogeneic reaction, might be preferred therapeutically where immediate effector response, e.g., inflammatory response, is not desired.
• na ⁇ ve CD4 + T cells exposed to autologous TSLP/IL-50-activated DC can lack immediate effector function, but can be stimulated to differentiate into effector cells by secondary stimulation.
• Na ⁇ ve CD4 + T cells were treated for seven days with autologous TSLP/IL-50-activated DC, followed by washing of the cells. The cells were then titrated with anti-CD3 with constant levels of anti-CD28, in order to cause TCR signaling. As a control, na ⁇ ve CD4 + T cells were also titrated with anti-CD3 with constant levels of anti- CD28. Separate incubation mixtures contained anti-CD3 at 0.0001, 0.0003, 0.001, 0.003,
• na ⁇ ve CD4 + T cells were maximally stimulated to proliferate with anti-CD28 at about 3.0 microgram ml, with little or no stimulation found with lower levels of anti-CD28.
• na ⁇ ve CD4 + T cells treated with autologous TSLP/IL-50-activated DC were maximally stimulated to proliferate at much lower levels of anti-CD28, i.e., at about 0.1 microgram ml.
• CD4 + T cells expanded with autologous TSLP/IL-50-activated DC have a reduced threshold of activation.
• TSLP/IL-50 (SEQ ID NO: Inactivated DC induces proliferation of various CD4 + T cells.
• TSLP/IL-50 (SEQ ID NO: l)-activated DC were incubated with autologous:
• T cells was found to occur with DC/T cells at the 1 :1 ratio. Proliferation of na ⁇ ve T cells was generally 1.2 to 1.8-fold greater than proliferation of central memory T cells, while proliferation of central memory T cells was generally about 2-fold greater than that of effector T cells. Controls incubated with each of the three types of T cells resulted in little or no induction of T cell proliferation.
• Hair follicle and eccrine gland staining in the ten normal subjects ranged from negative or low. Keratinocyte staining from the ten psoriatic subjects was high, where hair follicle and eccrine gland staining was comparatively lower. The results demonstrated a significant association between TSLP/IL-50 expression and psoriasis.
• SEQ ID NO:2 is IL-7R-alpha chain.
• SEQ ID NO:3 is TSLP receptor (TSLPR).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Immunology (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Pulmonology (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Toxicology (AREA)
• Rheumatology (AREA)
• Cell Biology (AREA)
• Dermatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Pain & Pain Management (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (2)

Family

ID=27734298

Family Applications (1)

Country Status (11)

Cited By (14)

Families Citing this family (11)

Family Cites Families (20)

• 2003
  • 2003-01-30 DK DK10011810.8T patent/DK2311869T3/da active
  • 2003-01-30 JP JP2003565411A patent/JP2005516606A/ja active Pending
  • 2003-01-30 CA CA2474011A patent/CA2474011C/en not_active Expired - Lifetime
  • 2003-01-30 NZ NZ533987A patent/NZ533987A/en not_active IP Right Cessation
  • 2003-01-30 EP EP09005325A patent/EP2077277A1/en not_active Withdrawn
  • 2003-01-30 EP EP03707610A patent/EP1487865A4/en not_active Withdrawn
  • 2003-01-30 US US10/354,951 patent/US20030186875A1/en not_active Abandoned
  • 2003-01-30 AU AU2003208888A patent/AU2003208888B2/en not_active Expired
  • 2003-01-30 EP EP10011810.8A patent/EP2311869B2/en not_active Expired - Lifetime
  • 2003-01-30 WO PCT/US2003/002758 patent/WO2003065985A2/en not_active Ceased
  • 2003-01-30 MX MXPA04007426A patent/MXPA04007426A/es active IP Right Grant
  • 2003-01-30 ES ES10011810T patent/ES2399503T5/es not_active Expired - Lifetime
  • 2003-01-30 PT PT100118108T patent/PT2311869E/pt unknown
• 2006
  • 2006-09-22 US US11/525,644 patent/US20070020262A1/en not_active Abandoned
• 2007
  • 2007-09-24 US US11/859,989 patent/US20090017018A1/en not_active Abandoned
• 2009
  • 2009-03-12 JP JP2009060287A patent/JP5519946B2/ja not_active Expired - Lifetime
  • 2009-11-10 US US12/615,728 patent/US20100136003A1/en not_active Abandoned
• 2011
  • 2011-03-21 US US13/052,404 patent/US20110229434A1/en not_active Abandoned
• 2012
  • 2012-06-20 JP JP2012138672A patent/JP2012184259A/ja active Pending
• 2014
  • 2014-05-19 JP JP2014103683A patent/JP2014156478A/ja active Pending

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events